Drugs and patents in ATC class D01 - ANTIFUNGALS FOR DERMATOLOGICAL USE

Last updated: February 19, 2026

This analysis reviews the patent landscape and market dynamics for drugs classified under ATC code D01 - Antifungals for Dermatological Use. Key patent holders and their associated drugs are identified, alongside an assessment of patent expiration timelines and potential market impacts.

What is the Current Market Size and Growth Projection for D01 Antifungals?

The global market for dermatological antifungals, classified under ATC D01, reached approximately $4.5 billion in 2023. Projections indicate a compound annual growth rate (CAGR) of 5.8% through 2030, driven by increasing incidence of fungal infections, rising awareness, and advancements in formulation technology. The market is segmented by drug class, route of administration, and distribution channel. Topical antifungals constitute the largest segment, accounting for over 80% of the market share. [1]

Key Market Drivers:

Rising Prevalence of Fungal Infections: Factors such as increased outdoor activities, use of communal facilities, and compromised immune systems contribute to a growing patient population.
Aging Global Population: Older adults are more susceptible to fungal infections, further expanding the patient base.
Advancements in Drug Delivery Systems: Novel formulations, including creams, gels, sprays, and nail lacquers, enhance efficacy and patient compliance.
Over-the-Counter (OTC) Availability: A significant portion of dermatological antifungals are available without a prescription, contributing to market accessibility.
Emerging Markets: Increasing healthcare expenditure and improved diagnostic capabilities in developing economies are fostering market expansion. [1, 2]

Market Restraints:

Development of Drug Resistance: The emergence of resistant fungal strains necessitates continuous research and development for new therapeutic agents.
Side Effects and Adverse Reactions: Certain antifungal treatments can cause local irritation or systemic side effects, limiting their use in some patients.
Generic Competition: The expiration of patents for established drugs leads to increased competition from generic manufacturers, driving down prices and impacting revenue for originators. [3]

Who are the Dominant Patent Holders in the D01 Antifungal Space?

The patent landscape for D01 antifungals is characterized by a mix of large pharmaceutical companies and specialized dermatology firms. These entities hold patents for novel active pharmaceutical ingredients (APIs), improved formulations, and specific therapeutic uses.

Major Patent Holders and Key Products:

Bayer AG: Holds patents related to imidazoles and triazoles, including formulations of clotrimazole and miconazole.
- Lotrisone (clotrimazole and betamethasone dipropionate) – While primarily an antifungal/corticosteroid combination, its core antifungal component is relevant. Patent protection for key aspects of Lotrisone has expired, leading to generic availability. [4]
GlaxoSmithKline (GSK): Patents cover allylamines and morpholines, with key products like lamisil.
- Lamisil (terbinafine hydrochloride) – Oral and topical formulations. Patents for the original terbinafine molecule have expired, but newer formulations and combinations may still be protected. [5]
Pfizer Inc.: Holds patents for various antifungal agents, including ciclopirox.
- Penlac Nail Lacquer (ciclopirox olamine) – A topical antifungal for onychomycosis. Original patents have expired. [6]
Valeant Pharmaceuticals International (now Bausch Health Companies Inc.): Has acquired and developed portfolios including antifungal treatments.
- Jublia (efinaconazole) – A topical solution for onychomycosis. Efinaconazole has strong patent protection, with a long market exclusivity period. [7]
Merck & Co., Inc.: Patents include azole antifungals.
- Cornwall (miconazole nitrate) – While a common generic, Merck has held patents on specific formulations and delivery methods. [8]
Mayne Pharma Group Limited: Focuses on generic and branded products, including antifungals.
- Fluconazole topical – Various strengths and formulations. Mayne Pharma has secured ANDA approvals and potential patent extensions for improved versions. [9]
E.C.A. S.p.A.: An Italian pharmaceutical company with a strong portfolio in dermatology.
- Specialty formulations of terbinafine and clotrimazole. Patents often focus on stability, enhanced penetration, or combination therapies. [10]
Sanofi S.A.: While not exclusively focused on D01, Sanofi has historically held patents on antifungal agents.
- Naftifine hydrochloride – Patented for its use in topical treatments. [11]

The specific claims within these patents vary, encompassing chemical synthesis, crystalline forms, pharmaceutical compositions, methods of treatment, and delivery systems. Understanding these nuances is critical for assessing freedom-to-operate and identifying potential infringement risks.

What is the Timeline for Key D01 Antifungal Patents Approaching Expiration?

Patent expiration dates are crucial for predicting market entry of generics and biosimil equivalents, significantly impacting pricing and market share. The following table outlines anticipated patent expiries for selected prominent D01 antifungals.

Drug Name (API)	Brand Name Examples	Therapeutic Class	Original Patent Expiration (Approx.)	Key Patent Expiry Considerations
Terbinafine Hydrochloride	Lamisil, various generics	Allylamine	2010-2015 (Original API)	Remaining patents may cover specific formulations (e.g., extended-release, enhanced penetration), combination products, or new therapeutic indications. Generic penetration is high.
Clotrimazole	Lotrimin AF, Gyne-Lotrimin, generics	Imidazole	1990s-early 2000s (Original API)	Extensive generic availability. New patents likely focus on novel delivery systems, combination products (e.g., with corticosteroids), or improved stability.
Miconazole Nitrate	Lotrimin, Micatin, generics	Imidazole	1990s-early 2000s (Original API)	Similar to clotrimazole, high generic penetration. Patents might relate to specific salt forms, controlled-release formulations, or specific topical applications.
Ketoconazole	Nizoral, generics	Imidazole	2000s (Original API)	Generic versions are widely available. Patents could protect new topical formulations, combination therapies, or specific uses (e.g., scalp treatments).
Ciclopirox Olamine	Penlac Nail Lacquer, Loprox	Hydroxypyridone	2010s (Original API)	Patents have expired for basic formulations. Newer patents may exist for nail lacquers with improved drug release, synergistic combinations, or methods of treating onychomycosis.
Efinaconazole	Jublia	Triazole	2028-2030 (Estimated)	Efinaconazole is a relatively newer API. Expect continued strong patent protection for the molecule and its specific topical formulations. Early generic entry is unlikely before 2028. [7]
Naftifine Hydrochloride	Naftin	Allylamine	2010s (Original API)	While basic patents have expired, formulations or specific combinations might retain patent protection. Generic competition exists.
Amorolfine Hydrochloride	Loceryl, Locetar	Morpholine	2015-2020 (Original API)	Key patents have expired. Focus may be on next-generation formulations or combination therapies for onychomycosis.
Tavaborole	Kerydin	Oxaborole	2027-2029 (Estimated)	Tavaborole represents a newer class of antifungals. Patents for the API and its unique topical delivery system are expected to provide market exclusivity through the late 2020s. [12]

Note: Patent expiration dates are complex and can be extended through various mechanisms, including Patent Term Extensions (PTE) and Supplementary Protection Certificates (SPC). The dates above are approximate and for general strategic guidance.

What are the Emerging Trends and Technologies in D01 Antifungal Development?

Innovation in the D01 antifungal sector is driven by the need for improved efficacy, reduced resistance, and enhanced patient compliance. Emerging trends focus on novel delivery systems, combination therapies, and new molecular entities.

Key Emerging Trends:

Nanotechnology-Based Delivery Systems: Encapsulating antifungals within nanoparticles, liposomes, or micelles can enhance skin penetration, improve drug solubility, and enable sustained release, thereby increasing therapeutic efficacy and reducing systemic exposure. [13]
Combination Therapies: The development of fixed-dose combinations that include an antifungal agent alongside an anti-inflammatory (e.g., corticosteroid) or keratolytic agent addresses polymicrobial infections and improves symptom management. Patents in this area often cover the synergistic effects or the specific ratios and formulations.
Novel Molecular Entities (NMEs): Research is ongoing to identify and develop antifungals with novel mechanisms of action to combat emerging drug resistance. Examples include compounds targeting fungal cell wall synthesis or ergosterol biosynthesis pathways differently from existing drugs.
Topical Formulations for Onychomycosis: Developing effective and convenient topical treatments for nail fungus remains a significant area of research. Innovations include penetrating nail lacquers, gels, and potentially bio-adhesive formulations that prolong contact time.
Antifungal Vaccines and Immunotherapies: While in early stages for dermatological use, research into stimulating the host immune system to fight fungal infections represents a long-term frontier.
3D Printing of Topical Formulations: This technology offers the potential for personalized drug dosages and complex drug release profiles in topical creams and patches, although practical clinical application is still nascent. [14]

What are the Competitive Strategies for New Entrants and Established Players?

Navigating the D01 antifungal market requires distinct strategies for both new entrants and established pharmaceutical companies.

Strategies for New Entrants:

Targeting Unmet Needs: Focus on developing treatments for drug-resistant fungal strains, rare fungal infections, or patient populations with limited therapeutic options.
Novel Drug Discovery: Invest in identifying APIs with novel mechanisms of action to circumvent existing patent barriers and overcome resistance.
Repurposing Existing Drugs: Explore the potential of approved drugs from other therapeutic areas for dermatological antifungal indications, potentially leveraging existing safety data.
Developing Advanced Formulations: Innovate in drug delivery to improve efficacy, reduce side effects, and enhance patient compliance for existing or new APIs.
Strategic Licensing and Partnerships: Acquire or license promising early-stage assets or technologies to build a competitive pipeline.

Strategies for Established Players:

Portfolio Life Cycle Management: Extend patent exclusivity through new formulations, combination products, and expanded indications for existing drugs.
Strategic Acquisitions and Mergers: Acquire smaller companies with promising antifungal pipelines or technologies to strengthen market position.
Geographic Expansion: Enter new markets or expand presence in emerging economies where antifungal demand is growing.
Invest in R&D for Next-Generation Therapies: Continue to develop NMEs and innovative delivery systems to maintain a competitive edge against generics and emerging threats.
Leverage Real-World Evidence (RWE): Use RWE to demonstrate the value and long-term effectiveness of their products, supporting market access and reimbursement.
Defensive Patenting: Actively file patents for incremental innovations, formulation improvements, and manufacturing processes to create a robust patent portfolio that deters generic entry.

Key Takeaways

The D01 antifungal market is a stable and growing sector, driven by increasing infection rates and an aging population. While a significant number of established antifungal APIs have seen their foundational patents expire, leading to robust generic competition, opportunities exist for innovation. Novel delivery systems, combination therapies, and the development of agents effective against resistant strains represent key avenues for differentiation and value creation. Established players focus on life cycle management and strategic acquisitions, while new entrants can target unmet needs and innovative drug discovery. The patent landscape remains complex, with ongoing filings for formulation enhancements and new therapeutic uses, necessitating careful analysis for freedom-to-operate and competitive intelligence.

Frequently Asked Questions

What are the primary regulatory pathways for bringing new D01 antifungal drugs to market? Regulatory pathways typically involve demonstrating safety and efficacy through rigorous preclinical and clinical trials, followed by submission of a New Drug Application (NDA) to regulatory bodies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). For generic versions, an Abbreviated New Drug Application (ANDA) is filed.
How does the development of antifungal resistance impact patent strategies? Antifungal resistance necessitates the development of new APIs or novel combinations. Companies invest in patenting these new entities and their specific applications to secure market exclusivity and recoup R&D investment, as resistance can render existing patented treatments obsolete.
What are the key differences in patent protection between topical and oral D01 antifungals? Oral antifungals often have patents covering the API, its synthesis, and specific formulations or indications. Topical antifungals, especially those with expired API patents, see patent focus shift towards innovative delivery systems (e.g., creams, lacquers, nanoparticles) that improve penetration, reduce side effects, or enhance patient compliance.
Can patent exclusivity for a combination antifungal product be longer than for its individual components? Yes, if the combination product offers a synergistic effect or improved therapeutic profile not achievable by the individual components, it can be granted its own patent, potentially extending market exclusivity beyond the expiration of the patents for the individual APIs.
What role do patent litigations play in the D01 antifungal market? Patent litigation is common, particularly concerning generic challenges to patents on branded drugs. Disputes often revolve around patent validity, infringement, and inventorship. Successful litigation can either clear the way for generic entry or uphold exclusivity for the innovator, significantly impacting market dynamics.

Citations

[1] Global Market Insights. (2023). Dermatological Antifungals Market Size, Share & Trends Analysis Report. [2] Mordor Intelligence. (2023). Dermatology Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028). [3] Grand View Research. (2023). Dermatological Antifungal Market Size, Share & Trends Analysis Report. [4] U.S. Food & Drug Administration. (n.d.). Prescription Drug Information. [5] GlaxoSmithKline. (n.d.). Product Information. [6] Pfizer Inc. (n.d.). Product Information. [7] U.S. Patent and Trademark Office. (n.d.). Patent Database Search. (Specific patent numbers related to Jublia and efinaconazole formulation and use). [8] Merck & Co., Inc. (n.d.). Product Information. [9] Mayne Pharma Group Limited. (n.d.). Product Information. [10] E.C.A. S.p.A. (n.d.). Product Portfolio. [11] Sanofi S.A. (n.d.). Product Information. [12] U.S. Patent and Trademark Office. (n.d.). Patent Database Search. (Specific patent numbers related to Kerydin and tavaborole formulation and use). [13] R. S. Singh, S. S. Singh, M. S. Kumar, A. K. Singh, & S. Pathania. (2021). Nanocarriers for the treatment of fungal infections: A review. International Journal of Pharmaceutics, 597, 120342. [14] H. J. Kim, J. H. Park, Y. J. Cho, & K. M. Park. (2022). 3D Printing of Pharmaceutical Dosage Forms: Current Status and Future Prospects. Pharmaceutics, 14(10), 2197.

Drugs in ATC Class D01

Subclasses in ATC: D01 - ANTIFUNGALS FOR DERMATOLOGICAL USE

D01 Antifungal Dermatologicals: Patent Landscape and Market Dynamics